Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
Permanent URI for this collectionhttps://hdl.handle.net/11147/9
Browse
8 results
Search Results
Conference Object A Carbohydrate sulfotransferase mutant zebrafish shows importance of keratan sulfate proteoglycan in skeletal structure(Mary Ann Liebert, 2024) Basol, M.; Ersoz, E.; Özaktaş, Helin; Cakan-Akdogan, G.Article Citation - WoS: 2Citation - Scopus: 2Plasmonic Functional Assay Platform Determines the Therapeutic Profile of Cancer Cells(American Chemical Society, 2023) Çetin, Arif E.; Topkaya, Seda Nur; Yazıcı, Ziya Ata; Yalçın Özuysal, ÖzdenFunctional assay platforms could identify the biophysicalpropertiesof cells and their therapeutic response to drug treatments. Despitetheir strong ability to assess cellular pathways, functional assaysrequire large tissue samples, long-term cell culture, and bulk measurements.Even though such a drawback is still valid, these limitations didnot hinder the interest in these platforms for their capacity to revealdrug susceptibility. Some of the limitations could be overcome withsingle-cell functional assays by identifying subpopulations usingsmall sample volumes. Along this direction, in this article, we developeda high-throughput plasmonic functional assay platform to identifythe growth profile of cells and their therapeutic profile under therapiesusing mass and growth rate statistics of individual cells. Our technologycould determine populations' growth profiles using the growthrate data of multiple single cells of the same population. Evaluatingspectral variations based on the plasmonic diffraction field intensityimages in real time, we could simultaneously monitor the mass changefor the cells within the field of view of a camera with the capacityof > & SIM;500 cells/h scanning rate. Our technology could determinethe therapeutic profile of cells under cancer drugs within few hours,while the classical techniques require days to show reduction in viabilitydue to antitumor effects. The platform could reveal the heterogeneitywithin the therapeutic profile of populations and determine subpopulationsshowing resistance to drug therapies. As a proof-of-principle demonstration,we studied the growth profile of MCF-7 cells and their therapeuticbehavior to standard-of-care drugs that have antitumor effects asshown in the literature, including difluoromethylornithine (DFMO),5-fluorouracil (5-FU), paclitaxel (PTX), and doxorubicin (Dox). Wesuccessfully demonstrated the resistant behavior of an MCF-7 variantthat could survive in the presence of DFMO. More importantly, we couldprecisely identify synergic and antagonistic effects of drug combinationsbased on the order of use in cancer therapy. Rapidly assessing thetherapeutic profile of cancer cells, our plasmonic functional assayplatform could be used to reveal personalized drug therapies for cancerpatients.Conference Object Brain Lipid Profile of Early Onset Tay-Sachs Disease Mouse Model(Springernature, 2020) Şengül, Tuğçe; Can, Melike; Akyıldız Demir, Seçil; Klose, C.; Surma, M.; Seyrantepe, Volkan[Abstract Not Available]Conference Object Role of Oxidative Stress in the Pathogenesis of Tay-Sachs Disease Mouse Model(Springernature, 2020) Ateş, Nurselin; Başırlı, Hatice Hande; Çalışkan, Tufan Utku; Nalbant, Ayten; Seyrantepe, Volkan[Abstract Not Available]Conference Object Hormones and the Breast: Local and Environmental Interactions(American Association for Cancer Research, 2012) Brisken, C.; Rajaram, R.; Ayyannan, A.; Beleut, M.; Yalçın, ÖzdenA woman's reproductive history affects her risk to get breast cancer. In particular, the number of menstrual cycles she experiences correlates with risk. We use tissue recombination experiments and different mouse mutant models to discern the roles of the ovarian hormones estrogens and progesterone act in the mammary gland. While estrogens drive pubertal development, progesterone is the major driver of proliferation in the adult mammary epithelium. Both steroids rely strongly on paracrine signaling to elicit cell proliferation and other biological effects.Conference Object Effects of Placental Derived Mesenchymal Stem Cells on Experimental Asthma(Wiley, 2015) Micili, Cilaker S.; Sözmen, Çağlayan S.; Karaman, M.; Baran, Yusuf; Kartal Yandım, Melis; Kiraz, Yağmur; Karaman, O.[No abstract available]Conference Object Determination of Therapeutic Potential of Luteolin for Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia Cells(Wiley, 2020) Gürler, Sevim Beyza; Baran, Yusuf; Kiraz, Yağmur[No abstract available]Article Citation - WoS: 15Citation - Scopus: 13Cascade Therapy With Doxorubicin and Survivin-Targeted Tailored Nanoparticles: an Effective Alternative for Sensitization of Cancer Cells To Chemotherapy(Elsevier Ltd., 2019) Dağlıoğlu, Cenk; Kacı, Fatma NecmiyeChemotherapy frequently involves combination treatment protocols to maximize tumor cell killing. Unfortunately these intensive chemotherapeutic regimes, often show disappointing results due to the development of drug resistance and higher nonspecific toxicity on normal tissues. In cancer treatment, it is critically important to minimize toxicity while preserving efficacy. We have previously addressed this issue and proposed a nanoparticle-based combination therapy involving both a molecularly targeted therapy and chemotherapeutic agent for neutralizing antiapoptotic survivin (BIRC5) to potentiate the efficacy of doxorubicin (DOX). Although the particles exhibited strong anticancer effect on the lung carcinoma A549 and the cervical carcinoma HeLa cells, there were lower-level therapeutic outcomes on the colon carcinoma HCT-116, the leukemia Jurkat and the pancreatic carcinoma MIA PaCa-2 cells. Since targeted therapies are one of the key approaches for overcoming drug resistance, tailoring the treatment of cancer cells with distinct characteristics is necessary to improve the therapeutic outcome of cancer therapy and to minimize potential pharmacokinetic interactions of drugs. In the light of this issue, this study examined whether a cascade therapy with low-dose DOX and survivin-targeted tailored nanoparticles is more effective at sensitizing HCT-116, Jurkat and MIA PaCa-2 cancer cells to DOX-chemotherapy than simultaneous combination therapy. The results demonstrated that the sequential therapy with the protocol comprising addition of the nanoparticles after incubation of cells with DOX clearly advanced the therapeutic outcome of related cancer cells, whereas the reverse protocol resulted in a reduction or delay in apoptosis, emphasizing the critical importance of formulating synergistic drug combinations in cancer therapy.